Thursday, February 01, 2007

$20 Million Series B Completed By Xcellerex - 2007-01-30 11:42:56 | Venture Capital News

"Xcellerex, Inc. announced today that it has completed a $20 million Series B financing, raising a second tranche of $11 million, to accelerate the commercialization of its disposable manufacturing technology for vaccines and biotherapeutics. SCG Group and Kleiner Perkins Caufield and Byers led the round. In connection with the financing, Kleiner Perkins Partner, Thomas Monath, M.D., has joined the Xcellerex board of directors.
Xcellerex is commercializing a highly innovative, modular and scalable manufacturing platform, FlexFactory™, which combines single use, disposable components and production-scale disposable stirred tank bioreactor systems (XDR™). The use of disposable components provides the flexibility to produce multiple products at a common facility, and to establish manufacturing capacity rapidly at dramatically lower costs than traditional fixed tank, hard-piped facilities. Along with its high throughput process development and formulation technologies, Xcellerex provides a fully integrated manufacturing approach with potential across the full range of cell production types. In addition, the portability of the FlexFactory technology enables distributed manufacturing to provide local drug supply capability. "

No comments: